Risk factors for developing hepatocellular carcinoma in patients treated with direct-acting antivirals I. Santana-Salgado, A. Bautista-Santos, R. Moreno-Alcántar

Access to direct-acting antivirals for the treatment of hepatitis C in a country with limited resources S. Marciano, L. Haddad, S.M. Borzi, C. D’Amico, L.A. Gaite, M.V. Aubone, M.E. Sirotinsky, N. Ratusnu, M.S. Frola, M.C. Aparicio, B. Ríos, M.N. Anselmo, R. Hansen, S. De Filippi, C. García Dans, L. de Labra, M.A. Peche, T.M. Strella, M. Ibáñez Duran, M.B. García Rosales, M. Dirchwolf, O.A. Galdame, A.C. Gadano

Pharmacologic management of patients with hepatic and pancreatic diseases that involve immunosuppressive therapies. Positioning within the framework of the SARS-CoV-2 (COVID-19) pandemic G. Miranda-Zazueta, J.A. González-Regueiro, I. García-Juárez, C. Moctezuma-Velázquez, F.J. López-Díaz, B. Pérez-González, L.F. Uscanga-Domínguez, M. Peláez-Luna